The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of outcomes over time (1998-2009) of patients (pts) with stage III colon cancer receiving adjuvant FOLFOX: Analysis of 7,230 patients from MOSAIC, C07, C08, N0147, AVANT, and PETACC8 trials in the ACCENT Database.
 
Mohamed E. Salem
Consulting or Advisory Role - Genentech/Roche; Taiho Pharmaceutical
Speakers' Bureau - Genentech/Roche; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Taiho Pharmaceutical (Inst)
 
Jun Yin
No Relationships to Disclose
 
Richard M. Goldberg
Honoraria - Baxter; Biothera; Forty Seven; Immunocare Therapies; kanghong Pharma; Merck; Merck KGaA; Merrimack; Pfizer; Taiho Pharmaceutical; Targovax
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Baxter; Merck KGaA; Sanofi
 
Levi Pederson
No Relationships to Disclose
 
Norman Wolmark
No Relationships to Disclose
 
Steven R. Alberts
No Relationships to Disclose
 
Julien Taieb
No Relationships to Disclose
 
John Marshall
Honoraria - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Bayer/Onyx; Caris Life Sciences; Celgene; Genentech/Roche; Taiho Pharmaceutical
Speakers' Bureau - Amgen; Bayer/Onyx; Genentech/Roche
Research Funding - Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Genentech/Roche (Inst); MedImmune (Inst); Pfizer (Inst)
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Bayer
Speakers' Bureau - Lilly; Roche
Research Funding - Sanofi
 
Takayuki Yoshino
Research Funding - Boehringer Ingelheim (Inst); GlaxoSmithKline K.K. (Inst)
 
Rachel Kerr
No Relationships to Disclose
 
Greg Yothers
No Relationships to Disclose
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; Merck Sharp & Dohme
 
Thierry Andre
Honoraria - Baxter; BAYER; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Novartis; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche/Genentech
 
Aimery De Gramont
Honoraria - Chugai Pharma; Yakult Pharmaceutical
 
Qian Shi
No Relationships to Disclose